The cytokine interleukin-6 (IL-6), whose bioactivity is enhanced in the presence of its soluble receptor (IL-6sR; see Refs. 34, 40) , stimulates osteoclastogenesis and bone resorption (36) . We recently reported that IL-6 plays an important role in PTH-induced bone resorption in vivo (15) . Circulating levels of both IL-6 and IL-6 soluble receptor (IL-6sR) are increased in humans and rodents in response to chronic PTH excess and short-term low-dose PTH infusion (15, 16) . The tissue source(s) of the systemic IL-6 and IL-6sR released in response to PTH is uncertain. Bone may contribute, since bone marrow stromal/osteoblastic cells produce IL-6 after treatment with PTH in vitro (10, 14, 19, 22, 26, 27, 32, 38) , but other organs may also play a role. The liver expresses high levels of IL-6 (42), IL-6sR (1, 8) , and the PTH/PTHRP receptor (41, 43) , and PTH has previously been shown to be active in hepatic tissue (6, 18, 21, 23, 24, 29, 30, 31) . We therefore investigated the possibility that the liver contributes to PTH-induced upregulation of systemic levels of IL-6 and IL-6sR. Our results demonstrate that PTH potently induces hepatic production of bioactive IL-6 and its soluble receptor by the rat liver ex vivo and that hepatocytes, liver endothelial cells, and Kupffer cells each produce IL-6 and IL-6sR in response to PTH in vitro.
MATERIALS AND METHODS
Reagents. Human PTH-(1™84) and bovine PTH-(7™34) were purchased from Bachem (King of Prussia, PA). Human calcitonin, type IV placental collagen, and FBS were obtained from Sigma (St. Louis, MO). Monoclonal rat anti-mouse IL-6, polyclonal goat anti-mouse/rat IL-6 antibody, and recombinant murine IL-6 protein were purchased from R&D Systems (Minneapolis, MN). Reagents for staining liver endothelial cells for uptake of di-I-acetylated low-density lipoprotein (LDL) were obtained from Biomedical Technologies (Stoughton, MA).
Perfusion of the isolated rat liver. Perfusion of the isolated rat liver was performed as previously described (24) . In brief, mature (250-350 g) male Sprague-Dawley rats (Taconic, Germantown, NY) were anesthetized with pentobarbital so-dium (50 mg/kg body wt) administered by intraperitoneal injection. The abdomen was opened, and the pancreaticoduodenal branch of the portal vein was ligated. A ligature was placed around the inferior vena cava (IVC) above the renal veins, and the IVC was injected with 500 units of heparin. The portal vein was cannulated with a 14-gauge Teflon catheter, and the liver was perfused at 37°C at a rate of 30 ml/min with Krebs solution (118 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO 4 , 1.2 mM MgSO 4 , 1.2 mM MgSO 4 , 2.5 mM CaCl 2 , 25 mM NaHCO 3 , 5.5 mM glucose, and 200 U/100 ml heparin), oxygenated with 95% O 2 -5% CO 2 . After cannulation of the supradiaphragmatic IVC and ligation of the IVC above the renal veins, the liver was transferred to a temperaturecontrolled perfusion chamber and continuously perfused via the portal vein in a single-pass fashion at a rate of 40 ml/min with buffer containing no heparin. The buffer was continuously gassed with the 95% O 2 -5% CO 2 mixture, and the temperature was monitored with a thermistor probe inserted between the lobes of the liver. Test peptides or vehicle control was added to the perfusate by means of a syringe pump programmed to deliver 400 l/min of a 100ϫ stock solution. Two-milliliter aliquots of the hepatic effluent were collected at 10 to 20-min intervals for 130 min from the catheter placed in the IVC. The effluent was stored at Ϫ70°C until analyzed for IL-6 or IL-6sR immunoreactivity or IL-6 bioactivity. The viability of each perfusion was assessed by measurement of perfusion pressure and oxygen consumption. Oxygen consumption was measured using a Lex-O 2 -Con instrument (Cavitron, Anaheim, CA) at timed intervals. Adequacy of perfusion was assessed in each experiment by trypan blue distribution within the liver.
Tissue culture. Hepatocytes were isolated from livers of Sprague-Dawley rats by low-speed centrifugation after in situ collagenase perfusion, as previously reported (3). The hepatocyte fraction was resuspended in Lebovitz media containing 10% FBS and seeded in six-well plates at a density of 7.5 ϫ 10 5 cells/well. After 1 h, the cultures were treated for either 2 or 4 h with 10 Ϫ8 M human PTH-(1™84) or its vehicle. At the end of the treatment period, the conditioned media were collected and stored at Ϫ20°C until assayed for IL-6 or IL-6sR. Cell viability, as assessed by trypan blue exclusion, was at least 95% at the conclusion of the treatment period.
Hepatic sinusoidal endothelial cells and Kupffer cells were isolated from livers of Sprague-Dawley rats by in situ pronase-collagenase digestion followed by density-gradient centrifugation and centrifugal elutriation, as previously described (9, 11) . Elutriated fractions of hepatic endothelial cells were collected using a Beckman JE-6B elutriation system at a pump speed of 20-22 ml/min, centrifuged at 350 g, resuspended in DMEM supplemented with 10% FBS, and seeded in six-well plates coated with type IV human placental collagen. The cells were maintained in culture for 24 h, at which point they were treated for 2 or 4 h with 10 Ϫ8 M human PTH-(1™84) or its vehicle. At the end of the treatment period, the conditioned media were harvested and assayed for IL-6 or IL-6sR. Staining for di-I-acetylated LDL, which was performed as previously described (39) , demonstrated equal numbers (on average 6 ϫ 10 5 ) of viable endothelial cells in the vehicle-and PTH-treated wells at the conclusion of the experiments.
Elutriated fractions of Kupffer cells were collected at a pump speed of 36 ml/min, centrifuged at 1,800 rpm for 7 min, resuspended in medium 199 containing 10% FBS, plated in 24-well plates at a density of 1 ϫ 10 6 cells/well, and cultured for 24 h before addition of 10 Ϫ8 M PTH-(1™84) or its vehicle. At the end of the treatment period, the conditioned media were harvested and assayed for IL-6 or IL-6sR. Hepatic stellate cells were prepared as previously reported using in situ perfusion and density gradient centrifugation and plated at a density of 5 ϫ 10 5 cells/well. Cell purity exceeded 95% (11) .
IL-6 assays. Immunoreactive IL-6 was measured in liver effluent and tissue culture media using a murine solid-phase enzyme-linked immunosorbent assay (R&D Systems). Antibody incubation times were adjusted to increase the sensitivity of the assay. In our laboratory, the detection limit is 3.9 pg/ml. Any sample in which the level was undetectable was assigned a value of 1 pg/ml. The intra-assay and interassay coefficients of variation (CV) for this assay in our laboratory are 3.2 and 4.1%, respectively.
IL-6 bioactivity in the liver effluent or conditioned media from liver cell cultures was determined by the proliferation of the factor-dependent cell line B13.29 (B9), as previously described (32) . Briefly, 10 4 B9 cells were cultured with various dilutions of hepatic effluent or cell-conditioned media in 96-well flat-bottomed tissue culture plates (Costar, Cambridge, MA) for 72 h at 37°C in RPMI 1640 medium containing 2% FBS. Cells cultured in media alone served as the negative control. Proliferation was measured by the incorporation of [ 3 H]thymidine (1 Ci/well, 5-8 Ci/mmol) added during the last 16 h of culture. The cultures were harvested on an automated sample harvester (Cambridge Technologies, Cambridge, MA) using glass fiber filters. Radioactivity was measured with a scintillation spectrometer (Packard Instrument, Meriden, CT). Data are presented as means Ϯ SE of triplicate cultures. To confirm that the bioactivity noted in the liver effluent was due solely to the presence of IL-6, hepatic effluent was preincubated for 30 min with a polyclonal goat anti-mouse/rat IL-6 neutralizing antibody at a concentration of 2 g/ml before its addition to the B9 cell cultures. As a control in these neutralization experiments, a monoclonal neutralizing antibody to mouse IL-6 was used at a concentration of 0.1 g/ml.
IL-6sR assay. IL-6sR was measured in hepatic effluent and conditioned media as follows. Rat (monoclonal) anti-mouse IL-6 receptor (Sigma) was diluted to a working concentration of 2 g/ml in PBS without carrier protein. Ninety-six-well microplates (Costar) were immediately coated with 100 l/ well of the diluted antibody. The plate was sealed and incubated overnight at room temperature. Each well was then aspirated and washed with 400 l of wash buffer (0.05% Tween 20 in PBS, pH 7.4). The process was repeated for a total of three washes using a Bio-Tek autowasher. The wells were blocked with 300 l of block buffer (1% BSA, 5% sucrose in PBS with 0.05% sodium azide) for a minimum of 1 h at room temperature. The aspiration/wash cycle was then repeated as described above.
A seven-point standard curve using twofold serial dilutions of mouse IL-6sR (Diaclone, Besançon, France) was diluted in 0.1% BSA and 0.05% Tween 20 in Tris-buffered saline (20 mM Trizma base and 150 mM NaCl), pH 7.3. The standards range from 15 to 1,000 pg/ml. Tris-saline buffer (100 l) was added to each well, followed by the addition of 100 l of either standard or sample. After a 2-h incubation at room temperature, the plate was washed as before. Twohundred micoliters of polyclonal antibody (200 ng/ml) against IL-6sR conjugated to horseradish peroxidase (R&D) were then added followed by a 2-h incubation at room temperature. The aspiration/wash cycle was repeated as above followed by the addition of 100 l of equal volumes of hydrogen peroxide and tetramethylbenzidine (R&D). After a 30-min incubation at room temperature, the reaction was stopped with 50 l of 2 N sulfuric acid. The optical density of each well was determined by using a microplate reader set to 450 nm and to 540 nm for wavelength correction. Calculations were done using a computer-generated 4PL curve fit.
The sensitivity of the assay is 7 pg/ml. Any sample in which the level was undetectable was assigned a value of 4 pg/ml. The intra-assay CV was 2.9% and the interassay CV was 3.8%.
Detection of IL-6 transcripts in hepatocytes. Total RNA was isolated from rat hepatocytes using Trizol reagent (GIBCO-BRL). IL-6 mRNA was detected using the GeneAmp RNA PCR kit (Perkin-Elmer). Total RNA (2 g) was reverse transcribed with random hexamers. A DNA fragment of 426 bp was amplified by PCR using the following primers: 5Ј-GAGT-TGTGCAATGGCAATTCTG-3Ј (sense) and 5Ј-CCGAGTA-GACCTCATAGTGAC-3Ј (antisense). As a control for the amount of total RNA reverse transcribed, RNA was also used to amplify transcripts for glyceraldehyde-3Ј-phosphate dehydrogenase (GAPDH).
Statistical analyses. Statistical analyses were performed using the SAS statistical package, version 6.11 (SAS Institute, Durham, NC). Comparisons between the effects of the various peptides on cytokine immunoreactivity and bioactivity in effluents from isolated perfused rat livers were made using repeated-measures ANOVA. Comparisons between the effects of PTH and vehicle on production of IL-6 or IL-6sR by cultured liver cells were made using two-way ANOVA.
The study was approved by the Yale University Animal Care and Use Committee. Figure 1A summarizes levels of immunoreactive IL-6 in effluents collected at 10-to 20-min intervals from ex vivo rat livers. In preparations perfused with vehicle or 100 pM human calcitonin, IL-6 levels remained below 6 pg/ml throughout the 130-min procedure. In contrast, perfusion with 100 pM PTH-(1™84) induced a substantial increase in IL-6 production that became detectable after 40 min of the study and increased thereafter in a linear fashion to reach a mean value of 30.7 Ϯ 2.7 pg/ml at 130 min (P Ͻ 0.0001 vs. vehicle or calcitonin). PTH-(7™34) stimulated production of IL-6 that was intermediate in magnitude between that induced by PTH-(1™84) and either vehicle or calcitonin. The mean IL-6 level in hepatic effluent after 130 min of perfusion with PTH-(7™34) was 10.8 Ϯ 0.8 pg/ml [P Ͻ 0.0001 vs. vehicle, calcitonin, and PTH-(1™84)].
RESULTS

PTH stimulates production of immunoreactive IL-6 by the isolated rat liver.
PTH stimulates hepatic IL-6 production at physiological concentrations. Perfusion of the isolated rat liver with PTH-(1™84) induced IL-6 production in a dosedependent manner. Thus, as shown in Fig. 1B, 1 pM concentrations of PTH-(1™84) in the perfusate (equivalent to 2.4 pmol/h) resulted in IL-6 levels of 14.8 Ϯ 0.4 pg/ml at the end of the perfusion (P Ͻ 0.001 vs. vehicle). Given a perfusion rate of 40 ml/min, nearphysiological concentrations of PTH are therefore capable of inducing hepatic IL-6 production at a rate of 0.6 ng/min in this ex vivo system.
PTH stimulates hepatic production of the IL-6sR. PTH-(1™84) stimulated production of the IL-6sR by the isolated rat liver in a dose-dependent fashion. As demonstrated in Fig. 2 , levels of the IL-6sR in hepatic effluent collected after 10 min of perfusion with either vehicle or PTH were undetectable. Thereafter, IL-6sR levels in effluent from livers perfused with vehicle remained constant at a value of ϳ50 pg/ml throughout the study. Each concentration of PTH-(1™84) studied (1, 10, and 100 pM) induced hepatic production of IL-6sR that was significantly greater than that induced by perfusion with vehicle (P Ͻ 0.001). However, the time course of the increase in hepatic IL-6sR production in response to PTH was different from that observed for IL-6. Thus levels of the IL-6sR increased initially to reach a peak at 60 min and fell gradually thereafter, although they remained above control values at the conclusion of the 130-min perfusion period.
PTH-induced hepatic IL-6 is bioactive. To determine whether the immunoreactive IL-6 produced by the isolated rat liver in response to perfusion with PTH was biologically active, we tested the ability of effluent from isolated rat livers to induce proliferation of the B9 cell line, as described in MATERIALS AND METHODS. As shown in Fig. 3A , the IL-6 bioactivity in samples collected from livers perfused with PTH-(1™84), PTH-(7™34), calcitonin (all at 100 pM), or vehicle reflected the pattern of IL-6 immunoreactivity measured in the same samples. Neither calcitonin nor vehicle perfusion induced any change in IL-6 bioactivity over the 130-min experiment. In effluent from livers perfused with 100 pM PTH-(1™84), IL-6 bioactivity began to increase after 40 min and thereafter increased in a linear fashion to reach a level at 130 min that was five times greater than that detected in response to perfusion with either vehicle or calcitonin (P Ͻ 0.0001). As was true of IL-6 immunoreactivity, PTH-(7™34) induced IL-6 bioactivity that was intermediate between that observed in response to PTH-(1™84) and that induced by perfusion with either calcitonin or vehicle. Thus PTH-(7™34) induced 2.2-and 2.1-fold greater IL-6 bioactivities compared with vehicle or an equimolar concentration of calcitonin, respectively (P Ͻ 0.001).
PTH-(1™84) also induced production of bioactive IL-6 in a dose-dependent manner. As shown in Fig. 3B , 10 pM PTH-(1™84) stimulated bioactive IL-6 production that, at the end of the perfusion was 3.8-fold greater than that measured in effluent from livers perfused with vehicle (P Ͻ 0.001). Perfusion of 1 pM PTH-(1™84) induced a 1.5-fold increase in IL-6 bioactivity at 130 min over that observed with vehicle perfusion (P ϭ 0.08).
To confirm that the B9 cell proliferation induced by effluent from rat livers perfused with PTH-(1™84) was specifically attributable to IL-6, we examined the effect of adding neutralizing antisera to IL-6 to the bioassay. As shown in Fig. 3C , in the absence of antiserum, both recombinant murine IL-6 and effluent from a rat liver perfused with PTH-(1™84) induced significant B9 cell proliferation. The proliferative effects of recombinant murine IL-6 were blocked when either a monoclonal rat anti-mouse IL-6 antibody (0.1 g/ml) or a polyclonal goat antibody that reacts with both mouse and rat IL-6 (2 g/ml) was added (Fig. 3C, left) . However, only the antibody that recognizes rat IL-6 was capable of inhibiting the proliferative effects of the samples of effluent from rat livers perfused with PTH-(1™84) (Fig.  3C, right) . These data confirm that the B9 cell proliferation induced by the effluent from livers perfused with PTH was due to bioactive IL-6. Fig. 2 . PTH stimulates IL-6 soluble receptor (IL-6sR) production by the rat liver ex vivo. Isolated rat livers were perfused with human PTH-(1™84) at the concentrations indicated for 130 min. Hepatic effluent collected at the indicated time points during the perfusions was assayed for IL-6sR. Data are means Ϯ SE from 3 separate experiments. * P Ͻ 0.001 vs. vehicle. Fig. 3 . PTH-induced hepatic IL-6 is bioactive. A: isolated rat livers were perfused with human PTH-(1™84), bovine PTH-(7™34), human calcitonin (each at 100 pM), or vehicle for 130 min as described in MATERIALS AND METHODS. Hepatic effluent collected at the indicated time points during the perfusions was assayed for IL-6 bioactivity using the B9 cell proliferation assay, as described in MATERIALS AND METHODS. Data are means Ϯ SE from 3 separate experiments and are presented as degree of stimulation over cell proliferation induced by media alone. * P Ͻ 0.0001 vs. vehicle or calcitonin. B: isolated rat livers were perfused with human PTH-(1™84) at the concentrations indicated for 130 min. Hepatic effluent collected at the indicated time points during the perfusions was assayed for IL-6 bioactivity. Data are means Ϯ SE from 3 separate experiments. * P Ͻ 0.0001 vs. vehicle. C: recombinant murine IL-6 at the indicated concentrations (left) or the indicated dilutions of hepatic effluent collected after 130 min of perfusion of an isolated rat liver with 100 pM PTH-(1™84) (right) were added to the B9 cell proliferation assay in the absence of antibody (open bars), in the presence of 0.1 g/ml of a monoclonal antibody that neutralizes mouse IL-6 (solid bars), or in the presence of 2 g/ml of a polyclonal antibody that neutralizes both mouse and rat IL-6 (hatched bars).
Liver cells produce IL-6 and IL-6sR in response to PTH in vitro.
Immunoreactive IL-6 and IL-6sR were measured in conditioned media from rat liver cells, isolated and cultured as described in MATERIALS AND METHODS, and treated with 10 nM PTH-(1™84) or its vehicle for 2 or 4 h. In vitro data were obtained at this pharmacological PTH concentration only. Mean Ϯ SE levels of IL-6 and IL-6sR in the cell-conditioned media of each hepatic cell type at each time point are shown in Tables 1 and 2 , respectively. IL-6 was not detectable in Kupffer cell-conditioned medium from 9 of 20 wells treated with vehicle, whereas IL-6sR was not detectable in Kupffer cell-conditioned medium from 15 of 22 wells treated with vehicle and 1 of 22 wells treated with PTH.
As shown in Fig. 4 , hepatocytes, endothelial cells, and Kupffer cells, but not stellate cells, produced IL-6 in response to PTH treatment. PTH induced increases in IL-6 production by hepatocytes 2.0-and 2.2-fold at 2 and 4 h, respectively, over that measured in conditioned media from parallel cultures exposed to vehicle alone (P Ͻ 0.001 for each time point). A similar response was observed in liver endothelial cells. IL-6 immunoreactivity in conditioned media from cultured hepatic endothelial cells treated with PTH-(1™84) was increased 2.0-fold after 2 h and 1.7-fold after 4 h over that in media from vehicle-treated cultures (P Ͻ 0.001 for each time point). Kupffer cells also produced IL-6 in response to treatment with PTH-(1™84), with 4.0-and 3.4-fold increases observed at 2 and 4 h, respectively, over vehicle-treated cultures (P Ͻ 0.001 for each time point). There was no increase in IL-6 production by stellate cells in response to PTH treatment. IL-6 levels were 1.48-and 1.03-fold higher in media from PTHtreated cells than vehicle-treated cells [p ϭ not significant (NS) for each time point].
The effect of PTH-(1™84) treatment on IL-6sR production by the four types of liver cells in vitro is shown in Fig. 5 . As was the case for IL-6, PTH treatment induced significant increases in IL-6sR production in hepatocytes, endothelial cells, and Kupffer cells but not stellate cells. Hepatocytes responded to PTH treatment with 2.3-and 2.4-fold increases in IL-6sR production after 2 and 4 h, respectively (P Ͻ 0.001 vs. vehicle for each time point). IL-6sR production by hepatic endothelial cells was increased 1.9-and 1.8-fold by PTH at 2 and 4 h, respectively (P Ͻ 0.001 vs. vehicle for each time point). Production by Kupffer cells of IL-6sR in response to PTH was increased 4.3-and 3.6-fold over that in vehicle-treated cultures at 2 and 4 h, respectively. IL-6sR production by hepatic stellate cells in response to PTH was marginally increased over control values at 2 h (degree of stimulation 1.18, P Ͻ 0.01) but not at 4 h (degree of stimulation 1.04, P ϭ NS). Hepatocytes express mRNA for IL-6. To determine if the increased expression of IL-6 protein by hepatocytes was accompanied by changes in the level of IL-6 mRNA, semiquantitative RT-PCR was performed using total RNA isolated from hepatocytes at 1, 2, and 3 h after treatment with PTH. As shown in Fig. 6 , PTH induced a time-dependent increase in IL-6 transcript expression, whereas there was no change in levels of GAPDH mRNA. It should be noted that, although IL-6 mRNA was always detected, upregulation of transcript expression was not seen in all hepatocyte preparations examined, probably due to the low levels of IL-6 transcript expression in these cells and the modest degree of increase in protein levels (2.0-fold).
DISCUSSION
PTH regulates the circulating levels of IL-6 in humans and rodents such that serum levels of IL-6 are increased in the face of chronic PTH excess and shortterm PTH infusion and decreased in hypoparathyroidism (15, 16) . Changes in circulating levels of the IL-6sR also occur in response to PTH in the same direction as those observed for IL-6 (16). The current study demonstrates that perfusion of the isolated rat liver with near physiological concentrations of PTH-(1™84) stimulates production of both bioactive IL-6 and the IL-6sR. Mean levels of IL-6 in effluent from ex vivo rat livers perfused with 2.4 pmol/h PTH were 14.8 pg/ml, strikingly similar to systemic levels of IL-6 (14.4 pg/ml) observed in intact rats infused with 12.9 pmol/h PTH (15) . These data strongly suggest that hepatic production could contribute substantially to PTH-induced increases in systemic levels of IL-6 and its soluble receptor. We find that three of the four major liver cell types (hepatocytes, endothelial cells, and Kupffer cells) produce both IL-6 and IL-6sR in response to PTH in vitro. Given that hepatocytes constitute, by far, the majority of the cellular mass of the liver, it is likely that they are responsible for most of the PTH-induced hepatic production of IL-6 and IL-6sR.
The role of PTH in the regulation of calcium homeostasis is in part dependent on its ability to stimulate osteoclastic bone resorption. IL-6 promotes osteoclastogenesis (36) and plays an important role in mediating the bone-resorbing actions of PTH in vivo (15) . PTH stimulates production of IL-6 in both skeletal (10, 14, 19, 22, 26, 27, 32, 38) and hepatic (current study) tissue, and we can not yet determine whether the dependence of PTH-induced bone resorption on IL-6 is attributable to cytokine produced at either site or both. However, our current findings raise the possibility that PTH-induced, liver-derived IL-6 may act in an endocrine fashion and may have as a potential site of action, bone. That IL-6 can act in this fashion is suggested by recent evidence demonstrating that its systemic administration influences the hypothalamicpituitary-adrenal axis (33) . An endocrine action of liver-derived IL-6 on bone would potentially be augmented by the increased circulating levels of the IL6sR induced by PTH, since osteoclastogenesis induced by IL-6 in vitro is enhanced in the presence of its soluble receptor (40) . The IL-6sR also prolongs the half-life of circulating IL-6 in vivo, thereby augmenting further the biological actions of IL-6 (34).
IL-6 plays an important role in the acute phase response, acting to stimulate hepatic production of acute-phase proteins such as C-reactive protein (13, 17) . IL-6 knockout mice exhibit impaired synthesis of acute-phase proteins (25) , whereas hepatic overexpression of IL-6 in mice leads to exaggerated production of acute-phase proteins, an effect that is augmented by coexpression of the IL-6sR (35) . The findings that PTH influences hepatic production of IL-6 and IL-6sR raise the possibility that disorders of PTH production may be associated with altered acute-phase responses. To our knowledge, there are no published data addressing this possibility. However, Funk et al. (12) have demonstrated that systemic administration of PTHRP, which signals through the type 1 PTH/PTHRP receptor, stimulates an increase in the circulating level of the acutephase protein serum amyloid A in mice.
Our data provide further evidence that the liver is a target organ for PTH. The liver strongly expresses mRNA for the PTH/PTHRP receptor (41, 43) , which probably mediates the actions of PTH or PTHRP on production of IL-6 and its soluble receptor (current study), gluconeogenesis (21) , intracellular calcium mobilization (23), increased adenylate cyclase activity (6), insulin-like growth factor I production (7), and the acute-phase response (12) in liver tissue. It is unlikely that the PTH-2 receptor, which binds PTH more avidly than PTHRP, contributes to the effects of PTH on hepatic IL-6 production because, although it may be expressed in the liver, it is much less abundant there than the type 1 receptor (44) .
Having determined that the liver is an important source of the circulating IL-6 generated in response to PTH, we examined the cellular basis of this phenomenon. Our findings demonstrate that each of three liver cell types (hepatocytes, hepatic endothelial cells, and Kupffer cells) produce both IL-6 and IL-6sR in response to PTH. In contrast, hepatic stellate cells did not produce either cytokine in response to PTH. The finding that hepatocytes respond to PTH stimulation in vitro is consistent with previous studies that have Fig. 6 . PTH upregulates IL-6 mRNA expression in hepatocytes. RNA isolated from primary rat hepatocytes treated either with vehicle or PTH for 1, 2, or 3 h was subjected to RT-PCR as described in MATERIALS AND METHODS. The 426-bp IL-6 amplicon was visualized on a 1.5% agarose gel (top). To control for variation in the amount of RNA in each reaction glyceraldehyde-3-phosphate dehydrogenase was also amplified in each reaction (bottom).
demonstrated that PTH binds to hepatocytes (2, 37) and stimulates mobilization of intracellular calcium (23) , adenylate cyclase activity (29) , and gluconeogenesis (30) in cultured hepatocytes. Because hepatocytes are the predominant cell type in the liver, we examined the effect of PTH on IL-6 transcript expression in these cells. The observed increase in message expression suggests that either transcriptional activation or message stabilization is contributing to the increased IL-6 protein expression induced by PTH in hepatocytes. Binding of PTH to Kupffer cells has also been demonstrated previously (4) , and Kupffer cells have been implicated in hepatic degradation of PTH (4). In contrast, the current data are the first, to our knowledge, to demonstrate PTH responsiveness in hepatic endothelial cells.
We were surprised to observe stimulation of IL-6 production by the isolated rat liver in response to PTH-(7™34), since this peptide is generally considered to be biologically inactive. This finding suggests that PTH fragments may have biological activity in the liver and raises the possibility that there may be novel PTH receptors in this tissue. Indeed, some evidence exists to support the possibility that the PTH fragment containing amino acids 30-34 has biological activity (28) .
In summary, the current study demonstrates that the ex vivo rat liver produces bioactive IL-6 and the IL-6sR in response to near-physiological concentrations of PTH. Hepatocytes, hepatic endothelial cells, and Kupffer cells, but not hepatic stellate cells, each produce IL-6 and IL-6sR in response to PTH, but hepatocytes are likely to be responsible for the majority of PTH-induced hepatic production of cytokine and receptor. These results suggest that the liver contributes substantially to the regulation by PTH of circulating levels of IL-6 and its soluble receptor in vivo and raise the possibility that liver-derived cytokines may play a role in PTH-induced bone resorption.
